Gastrointestinal Stromal Tumors (GISTs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Gastrointestinal Stromal Tumors (GISTs) are the most ordinary mesenchymal neoplasms of the gastrointestinal tract. Approximately 80% of GISTs harbor activating mutations in the KIT or PDGFRA genes that are responsible for the up-regulation of crucial signaling pathways, including MAPK and PI3K-AKT. GISTs lacking KIT and PDGFRA mutations are referred to as “wild-type” (wt)-GIST. GISTs can develop in the colon, rectum, esophagus, mesentery, and omentum and are most commonly found in the stomach (60 percent) and small intestine (25 percent). They can also evolve in the colon, rectum, esophagus, mesentery, and omentum (15 percent together). Fatigue, abdominal pain, dysphagia, satiety, and obstruction are all symptoms associated with GISTs. One or more GISTs develop in 7% of patients with neurofibromatosis type I (NF1). Most cancers start in the small intestine and do not spread quickly. Most of these GISTs are KIT and PDGFRA wild-type, but as expected, they have somatic mutations or loss of the remaining wild-type NF1 allele, resulting in MAP kinase signaling.

·       In the United States, gastrointestinal stromal tumors (GISTs) incidence varies between 11 and 17 cases per million adults per year.

 

Thelansis’s “Gastrointestinal Stromal Tumors (GISTs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gastrointestinal Stromal Tumors (GISTs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Gastrointestinal Stromal Tumors (GISTs) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Gastrointestinal Stromal Tumors (GISTs) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Gastrointestinal Stromal Tumors (GISTs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Gastrointestinal Stromal Tumors (GISTs), Gastrointestinal Stromal Tumors (GISTs) market outlook, Gastrointestinal Stromal Tumors (GISTs) competitive landscape, Gastrointestinal Stromal Tumors (GISTs) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)